Melatonin could enhance the sensitivity of breast tumors to adriamycin in vivo.
Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer.
AI Summary
Key Findings
Abstract
OBJECTIVE: This study aims to investigate the protective and sensitive effects of melatonin (MLT) in the treatment of breast cancer. MATERIALS AND METHODS: ER+ breast cancer rat model was established and then rats were randomly divided into five different groups as follows: control group, Diss group, adriamycin (ADM) group, MLT group, and MLT combined with adriamycin (M+A) group. Tumor weights and one month survival rate were compared among these groups. In addition, changes of tumor tissues and expression of E-cadherin were observed under optical microscopy or electro-microscopy. RESULTS: Tumor weights were significantly lighter in M+A group than those in ADM group (p
Affiliation
C Ma
External References
- PubMed ID:
- 26050360
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.